In this follow-up study, we aimed to investigate the clinical management and outcomes of patients with advanced melanoma in the metastatic/unresectable and the adjuvant setting, approximately a decade after the introduction of ICIs and BRAF/MEKi into clinical use. Here, BRAF is linked to melanoma.